Rapid respiratory disease test Combo

for respiratory infectionsdiagnosticmultiparametric

Product overview
Multiple Respiratory Antigen Combo Test is a qualitative rapid lateral‑flow assay for the simultaneous detection of several common respiratory virus antigens from human nasal swab specimens. The panel is designed to assist rapid differential diagnosis when early clinical symptoms overlap and to support point‑of‑care decision making.

Target pathogens

• SARS‑CoV‑2 (COVID‑19)
• Respiratory syncytial virus (RSV)
• Influenza A virus
• Influenza B virus
• Adenoviruses

Key benefits

• Rapid turnaround: results in approximately 10–15 minutes.
• Multiplex qualitative detection: identifies presence or absence of multiple respiratory virus antigens from a single nasal swab.
• Simple workflow: no additional laboratory equipment required for routine use.
• Scalable for mass screening: format and procedure suitable for high‑throughput screening in hospitals, clinics and community testing sites.
• High analytical performance: reported sensitivity, specificity and overall accuracy >95%.
• Supports clinical management: helps differentiate pathogens with overlapping early symptoms to guide triage and infection‑control measures.

Intended specimen
Human nasal swab specimens (anterior nasal swab).

Usage scenarios

• Point‑of‑care testing in clinics, urgent care and outpatient settings.
• Rapid triage during respiratory infection seasons or outbreak response.
• Supplementary screening to support clinical assessment and infection‑control workflows.

Technical specifications

• Assay type: qualitative rapid antigen combo (multiplex lateral‑flow cassette).
• Sample type: human nasal swab.
• Time to result: ~10–15 minutes.
• Analytical performance: sensitivity, specificity and accuracy reported >95%.
• Operation: visual read; no specialized instrumentation required for routine use.
• Targets: SARS‑CoV‑2, RSV, Influenza A, Influenza B, Adenoviruses.
• Format: lateral‑flow rapid test cassette (immunochromatographic).